Prevail Therapeutics begins trading on NASDAQ
New York City-based Prevail Therapeutics, a gene therapy company, has gone public after pricing its over 7.3 million shares at $17 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol "PRVL." Morgan Stanley, BofA Merrill Lynch and Cowen are the lead underwriters. Prevail’s pre-IPO backers included OrbiMed, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners LP, Boxer Capital LLC, Adage Capital Management LP and Alexandria Venture Investments.
20 June 2019•2 mins read
